Tiotropium vs long‐acting beta‐agonists: Hospitalisations, number of participants with 1 or more exacerbations
Tiotropium probably leads to lower patients with 1 or more exacerbations compared with long‐acting beta‐agonists (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Tiotropium vs long‐acting beta‐agonists Patients with 1 or more exacerbations · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history Tiotropium probably leads to lower patients with 1 or more exacerbations compared with long‐acting beta‐agonists (moderate certainty). Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease (2012) · Cochrane Headline outcomes only | OR 0.86 [0.79, 0.93] | 6 studies · 12123 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.